The DOJ dropped a June 2024 indictment against a Cassava Sciences advisor, closing a case tied to an alleged short-selling ...

Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified ...

Cassava Sciences ( ($SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Facing charges from the Securities and Exchange Commission for misleading claims ...

Cassava shares are down 34c, or 12%, to $2.46 in pre-market trading after resuming following a halt for news pending. Published first on TheFly – the ultimate source for real-time, market-moving ...

News is the latest setback for the clinical-stage biotech, which was the subject of SEC and Justice Department investigations earlier this year Cassava Sciences Inc.'s stock tumbled 85% Monday to put ...

The average one-year price target for Cassava Sciences (NasdaqCM:SAVA) has been revised to $5.10 / share. This is an increase ...

Cassava Sciences (NASDAQ: SAVA) ended the week with a piece of dispiriting news. It's going to reach deep into its coffers to settle charges brought by the most important financial-markets regulator ...

Chris Cook, A Skilled Litigator, To Join Management Team as General Counsel New Position Is Expected to Be Critical to Operations and Strategic Initiatives “Chris is an accomplished legal advisor, a ...

Cassava Sciences (NASDAQ:SAVA) reported better-than-expected earnings with its Q3 2024 financials on Thursday and reaffirmed its timeline to deliver a key Phase 3 readout for its oral Alzheimer’s ...

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the trades showed up on publicly ...